Atrix Advances In Periodontal Disease

6 April 1997

Atrix Laboratories, the US drug delivery and medical device companybased in Fort Collins, Colorado, has filed a New Drug Application with the US Food and Drug Administration for marketing approval of Atridox, its treatment for periodontal disease.

Atridox combines the company's Atrigel biodegradable polymer with the antibiotic doxocycline, and has the potential to offer a major advance in the treatment of periodontitis, says the company.

Atridox "represents an innovative, non-invasive approach to therapy that is faster, less painful and less costly than mechanical scaling and root planing, currently the standard treatment for periodontitis," said John Urheim, vice chairman and chief executive of the company.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight